摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tetrakis(1,3,5-triaza-7-phosphaadamantane)platinum(0) | 194346-38-8

中文名称
——
中文别名
——
英文名称
tetrakis(1,3,5-triaza-7-phosphaadamantane)platinum(0)
英文别名
platinum;1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane
tetrakis(1,3,5-triaza-7-phosphaadamantane)platinum(0)化学式
CAS
194346-38-8
化学式
C24H48N12P4Pt
mdl
——
分子量
823.701
InChiKey
KZDYOSAEHJNOEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.64
  • 重原子数:
    41.0
  • 可旋转键数:
    4.0
  • 环数:
    16.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38.88
  • 氢给体数:
    0.0
  • 氢受体数:
    12.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tetrakis(1,3,5-triaza-7-phosphaadamantane)platinum(0) 在 NH4Cl or CO2 or C6H13N3P(1+) or C5H4NH(1+) 作用下, 以 重水 为溶剂, 生成
    参考文献:
    名称:
    Water-Soluble Organometallic Compounds. 7.1 Further Studies of 1,3,5-Triaza-7-Phosphaadamantane Derivatives of Group 10 Metals, Including Metal Carbonyls and Hydrides
    摘要:
    The syntheses of Ni(PTA)(4) (5), Pd(PTA)(4) (6), and Pt(PTA)(4) (8) are accomplished through the reduction of the (MCl2)-Cl-II salts in water with excess 1,3,5-triaza-7-phosphaadamantane (PTA). The products are obtained as partially protonated derivatives with protonation occurring at the nitrogen atoms of the bound PTA ligands. Crystal structures illustrating the monoprotonated and bis-protonated derivatives of 8, [Pt(PTA)(3)(PTAH)][Cl] (1S) and [Pt(PTA)(2)](PTA)(3)[BF4](2) (2S), are reported. The crystal structure of an intermediate along the reduction pathway, [PdCl(PTA)(3)][Cl] (7), is also presented, showing a trans influence whereby the Pd-P bond length trans to the Cl- ligand is shorter, 2.238(3) Angstrom, than the average Pd-P bond length cis to the Cl- ligand, 2.334(2) Angstrom. Complex 8 is also protonated at the metal center to form [(H)Pt(PTA)(4)][X], where X = Cl-, BF4-, HCO3-, and C3H5CO2-, through the addition of weak acids such as CO2/H2O, NH4Cl, PTAH(+)Cl(-), HPy+BF4-, and crotonic acid. Addition of strong acids such as HCl or HBF4 results in protonation at the PTA ligands. Thereby, the Pt metal center is shown to have a pK(a) between 7.44 and 9.25. The bound PTA ligands on complex 8 have a pK(a) below 4.69 but above 2.12. Ni(CO)(4-n)(PTA)(n) derivatives are also reported for n = 3 (9), 2 (10), and 1 (11). Using LR data of 11, PTA is determined to have an electronic parameter (chi) as defined by Tolman to be 15.3 cm(-1), indicating PTA to be slightly less donating than PPh3, where chi = 12.8 cm(-1). Complex 10 is crystallized out of a MeOH/ether solution maintained at -15 degrees C and characterized by X-ray crystallography. It is a distorted tetrahedron and has a crystallographically determined Tolman cone angle of PTA of 103 degrees. Monitored reactions of Ni(PTA)(4) with CO in water via in situ IR techniques show that the rate observed for the dissociation of PTA to provide Ni(CO)(PTA)(3) is 7.92 x 10(-4) s(-1) at 20 degrees C. This rate, along with P-31 NMR results, indicates that the M-0(TA)(4) complexes exhibit little dissociation and slow exchange of the bound PTA ligands.
    DOI:
    10.1021/ic981243j
  • 作为产物:
    参考文献:
    名称:
    Darensbourg, Donald J.; Decuir, Tara J.; Stafford, Nicole White, Inorganic Chemistry, 1997, vol. 36, # 19, p. 4218 - 4226
    摘要:
    DOI:
点击查看最新优质反应信息

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)